Clinical Trial Update: Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effects of a CB1 antagonist/reverse agonist (Rimonabant) on walking abilities in individuals with incomplete spinal cord i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Hospital Nacional de Parapléjicos de Toledo | Conditions: Spinal Cord Injuries | Phase 2 | Status: UNKNOWN